For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Dementia: Shifting the curve at individual and population level
Dementia: Shifting the curve at individual and population level

Specialist GP Ngaire Kerse summarises key points from a public lecture on population-level approaches to dementia risk reduction
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Walsh S, Merrick R, Brayne C. The relevance of social and commercial determinants for neurological health. Lancet Neurol 2022;21(12):1151–60.
2. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 2024;404(10452):572–628.
3. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013;382(9902):1405–12.